flow trial semaglutide nejm Oral and Cardiovascular Outcomes in Patients with Type 2 Diabetes Presented at #ERA24: FLOW trial:

For those who prefer no needles , oral GLP-1 options are now FDA-approved

A nasal spray must penetrate nasal mucosa, possibly deal with mucociliary clearance, and may have somewhat reduced bioavailability

Elevated GCG levels have been associated with changes in eGFR and sodium-fluid retention

According to the Mayo Clinic, some possible behavioral side effects in addition to suicidal thoughts, insomnia, and anxiety include: worsened depression, sudden and significant increases in energy, recklessness, emotional sensitivity or an easy time become upset, or strong feelings like nervousness, fear, or anger

Endometriosis affects approximately 10% of reproductive-age women and involves complex inflammatory, immune, and metabolic pathways

We look forward to seeing further results at CTAD, as this may suggest a path forward for semaglutide as part of a combination therapy approach